August 6, 2026 Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
July 30, 2026 Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
July 14, 2026 Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
May 28, 2026 Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 27, 2026 FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC) FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
May 7, 2026 Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
May 4, 2026 Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS) Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
April 30, 2026 Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
April 23, 2026 Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026 Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
March 4, 2026 Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
February 25, 2026 Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
February 18, 2026 Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
January 2, 2026 Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
November 10, 2025 Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
August 7, 2025 Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
May 7, 2025 Ironwood Pharmaceuticals Reports First Quarter 2025 Results Ironwood Pharmaceuticals Reports First Quarter 2025 Results
April 30, 2025 Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
April 25, 2025 Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
